In short
Clinical trials are investigating Hyoscine, here studied as scopolamine patches, for children with cerebral palsy who have troublesome drooling. These studies aim to compare how well it works over time and measure the impact on daily life. The target group is children aged 4 years and older with pathological drooling.
Key points
- Clinical trials investigating Hyoscine in the provided data focus on drooling in children with cerebral palsy. The main study compares a scopolamine patch with botulinum toxin injections into the salivary glands. It is a Phase 3 interventional trial and includes children aged 4 years and older. The study looks at how drooling changes over 15 months and how much it affects daily life. The trial is completed and enrolled 132 participants.
Trial overview
The main trial in the provided data is TOXSIALO-TRIAL, which studied treatment for drooling in children with cerebral palsy. It compared a scopolamine patch, which is a form of Hyoscine in this dataset, with botulinum toxin injections into the salivary glands. The study was completed and enrolled 132 participants.
Who was studied
The trial focused on children aged 4 years and older who had cerebral palsy and pathological drooling, meaning drooling that is a real medical problem rather than a small normal amount. The study description does not give more detailed participation rules, so only this target group can be confirmed from the source data.
What was tested
The trial tested a scopolamine patch against botulinum toxin injections as part of a standardized rehabilitation guidance plan. In the source data, the patch is listed as SCOPODERM TTS 1 mg/72 hours, and the injection treatment is listed as BOTOX 100 units. The goal was not simply to give treatment, but to compare which approach better reduced drooling over time.
Study design and phase
This was an interventional study, which means the researchers assigned treatments and then measured the results. It was a Phase 3 trial, a later stage of research that usually compares treatments in a larger group of patients. The study included 132 participants, which shows that it was designed to gather meaningful comparative data in a pediatric population.
Outcomes measured
The main outcome was the change in the degree and impact of drooling from the start of treatment to 15 months later. Researchers measured this using the DIS scale, which is a scoring tool for drooling severity and how much it affects daily life. This means the trial was not only asking whether drooling changed, but also whether the change mattered in everyday life for the child and family.
What the trial means for patients
For families, this trial is an example of research looking at practical ways to manage drooling in children with cerebral palsy. The study compares two active treatment approaches rather than testing Hyoscine alone against no treatment. Because the trial is completed, it adds information about how these options were studied over a long follow-up period of 15 months.